Evidence map›Paper›PMID 41589852›Full record

Trial reportAntimicrobial agents and chemotherapy2026

Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease.

Hyoung Jin Kang, Antonio C Arrieta, Catharina Dhooge, Ágnes Kelemen, Mercedes Macías-Parra, Lourdes Aranda, Yulia V Dinikina, Imad Kassis, Simone Cesaro, Aimee Shepherd and 4 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hyoung Jin KangSeoul National University College of Medicine, Seoul, Republic of Korea.
Antonio C ArrietaChildren's Hospital of Orange County, Orange, California, USA.ORCID 0000-0001-9281-8915
Catharina DhoogeGhent University Hospital, Ghent, Belgium.
Ágnes KelemenB.-A.Z. Vármegyei Central Hospital, Miskolc, Hungary.
Mercedes Macías-ParraInstituto Nacional de Pediatría, Mexico City, Mexico.
Lourdes ArandaHospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Yulia V DinikinaAlmazov National Medical Research Centre, Saint Petersburg, Russia.
Imad KassisRambam Medical Center, Haifa, Israel.
Simone CesaroAzienda Ospedaliera Universitaria Integrata, Verona, Italy.
Aimee ShepherdMerck & Co., Inc., Rahway, New Jersey, USA.
Arvind K ShahMerck & Co., Inc., Rahway, New Jersey, USA.
Tiffany MackeyMerck & Co., Inc. (author working under contract with Parexel International, Atlanta, GA, USA), Rahway, New Jersey, USA.
Hetty WaskinMerck & Co., Inc., Rahway, New Jersey, USA.
Matthew G JohnsonMerck & Co., Inc., Rahway, New Jersey, USA.ORCID 0000-0002-6023-1252

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Children with invasive aspergillosis (IA) experience significant morbidity and mortality. Posaconazole is a broad-spectrum triazole antifungal agent indicated for IA treatment in adolescents and adults. A phase 2, open-label, noncomparative, multinational clinical trial in pediatric participants (2-to-<18 years old, body weight ≥10 kg) with possible, probable, or proven IA was conducted. Participants received intravenous posaconazole for ≥1 week, after which they could switch to oral posaconazole for a total treatment duration

Indexed as

Antifungal AgentsAspergillosisInvasive Fungal InfectionsTriazolesAdministration, OralAdolescentChildChild, PreschoolFemaleHumansMaleTreatment OutcomeAntifungal AgentsposaconazoleTriazolesAspergilluschildreninvasive fungal infectionsinvasive mold infectionstriazole

Identifiers

PMID41589852
PMCPMC12959131

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.